positron emission tomography

Benperidol (Anquil) is a butanone analog with antipsychotic and stabilizing properties, and has been shown to be effective in blocking D2 receptors.Benperidol can be used in positron emission tomography (PET) scanning to measure D(2) dopamine receptor binding in vivo.Benperidol has been shown to be effective in blocking D2 receptors in vivo.Benperidol has been shown to be effective in blocking D2 receptors in vivo.

DPA-714 is a high-affinity translocator protein (TSPO) ligand (Ki=7 nM) designed with a fluorine atom, allowing labeling with fluorine-18 for in vivo imaging via positron emission tomography. [18F]DPA-714 successfully enables specific imaging of inflammation in various neuroinflammation models and a brain tumor model.

PK14105 has been evaluated biologically as a potential radioligand for positron emission tomography (PET) studies targeting peripheral benzodiazepine binding sites (PBBS) receptors. When administered to rats with unilaterally lesioned striata, PK14105 was observed to quickly cross the blood-brain barrier, displaying significant radioactivity retention in the lesioned striatum, in contrast to the unlesioned striatum or cerebellar vermis. Additionally, PK14105 has the capability to inhibit receptor ligands, calcium channel ligands, and co-transporters in all salivary glands.

Verubulin (MPC 6827) is a potent microtubule blocker with cytotoxic and potentially anticancer activity that disrupts newly formed blood vessels in xenografts, and can be used to image microtubules (MTs) using positron emission tomography (PET).

DOTA-NHS-ester is a linker for affibody molecules with applications in small animal PET, SPECT, and CT. It can be used to label radiotherapeutic agents or imaging probes for tumor detection.

MK-6240 is a tau positron emission tomography (PET) tracer for neurofibrillary tangles (NFTs) that exhibits high specificity and selectivity in binding to NFTs.

T807 (AV-1451) is a novel tracer of tau positron emission tomography (PET).

DOTA-NHS-ester (TFA) serves as a linker for affibody molecules, and it is applicable in small animal imaging techniques such as positron emission tomography (PET), single-photon emission computed tomography (SPECT), and CT scans. It can also be used to label radiopharmaceuticals or imaging probes for tumor detection.

PARP1-IN-29 is an orally active PARP-1 inhibitor with an IC50 of 6.3 nM. When labeled with [18F], PARP1-IN-29 can be utilized for positron emission tomography (PET) imaging, specifically targeting PARP-1 in tumors. This compound is useful in oncology and imaging studies, particularly for detecting PARP-1 activity in cancer.

[11C]MeS-IMPY exhibits a higher binding affinity for β-amyloid plaques extracted from Alzheimer's disease (AD) brains or AD brain homogenates than IMPY, with Ki values of 7.93 nM and 8.95 nM, respectively. [11C]MeS-IMPY is a potential radioactive ligand for positron emission tomography (PET) imaging of β-amyloid plaques.

PXT-012253 is a positron emission tomography (PET) ligand targeting mGluR4, designed to bind to its allosteric sites. This compound is useful for research related to Parkinson's disease and levodopa-induced movement disorders.

N-Methylspiroperidol is a D2 receptor antagonist. This compound can be labeled as [18F]N-Methylspiroperidol, which allows for the investigation of its interaction with 5-HT2C receptors via PET (positron emission tomography), as well as examining the competition and impact of neurotransmitters like dopamine on these receptors.

Lissamine rhodamine B, a new Radiotracer, is used for Imaging Tumors by Positron Emission Tomography.

L-FMAC F-18 has potential diagnostic activity during positron emission tomography (PET) imaging. After phosphorylation by DCK, the 18F moiety can be visualized by PET imaging.

(18F)LBT 999 is a positron emission tomography (PET) tracer, used for the quantification of the dopamine transporter (DAT) in the healthy rat brain.

DCFBC F-18 is a radioconjugate containing a low molecular weight tracer, DCFBC, specific for prostate-specific membrane antigen (PSMA) and labeled with the positron-emitting isotope F 18 with potential prostate tumor imaging upon positron emission tomogra

GSK931145 is a positron emission tomography (PET) radioligand, it is suitable for quantifying glycine transporter (GlyT1) availability in the living brain.

LMI-1195 is a 18F-labeled ligand for the norepinephrine transporter. LMI-1195 is used for mapping cardiac nerve terminals in vivo using positron emission tomography (PET).

PSMA-11 (HBED-CC-PSMA) detects prostate cancer recurrence and metastasis by binding to the extracellular structural domain of prostate-specific membrane antigen (PSMA).PSMA-11 is often used as a tracer of PSMA-expressing tumours in positron emission tomography (PET) scanning by intravenous injection of gallium Ga 68-labelled PSMA-11, Glu-urea-Lys(Ahx) molecule targeted and bound PSMA-expressing tumour cells. After internalisation, PSMA-expressing tumour cells could be detected on PET imaging.

Altanserin can binds to the 5-HT2A receptor. Labeled with the isotope fluorine-18 it is used as a radioligand in positron emission tomography (PET) studies of the brain.

Altanserin tartrate is a compound that binds to the 5-HT2A receptor. Labeled with the isotope fluorine-18 it is used as a radioligand in positron emission tomography (PET) studies of the brain.

Fet F-18 is an amino acid analog radiolabeled with fluorine F-18, a positron-emitting isotope, can be used as a tracer in positron emission tomography (PET).

MK-9470 is a selective, high-affinity reverse agonist and is also a fluorine 18 labeled positron emission tomography (PET) radiotracer [(18) F]. The MK-9470 has been used to image cannabinoid receptor type 1 in healthy and ill human brains.

ML 10 is is a [18F] positron emission tomography (PET) radiotracer that accumulates in cells presenting apoptosis-specific membrane alterations. [18F]ML-10 allows for the detection of apoptotic cells located in atherosclerotic plaques.